HepaRegenix lands €15m to advance liver regeneration drug into clinical ...
HepaRegenix secures €15M for HRX-215 trials, a MKK4 inhibitor promoting liver regeneration in diseased livers. Funded by Vesalius Biocapital IV, Novo Holdings, Boehringer Ingelheim Venture Fund, and High-Tech Gründerfonds, aiming to treat liver diseases and reduce transplant needs.
Reference News
HepaRegenix lands €15m to advance liver regeneration drug into clinical ...
HepaRegenix secures €15M for HRX-215 trials, a MKK4 inhibitor promoting liver regeneration in diseased livers. Funded by Vesalius Biocapital IV, Novo Holdings, Boehringer Ingelheim Venture Fund, and High-Tech Gründerfonds, aiming to treat liver diseases and reduce transplant needs.